Slideshare uses cookies to improve functionality and performance, and to provide you with relevant advertising. If you continue browsing the site, you agree to the use of cookies on this website. See our User Agreement and Privacy Policy.

Slideshare uses cookies to improve functionality and performance, and to provide you with relevant advertising. If you continue browsing the site, you agree to the use of cookies on this website. See our Privacy Policy and User Agreement for details.

2.
Mul$ple
Myeloma
• Malignancy
of
terminally
diﬀeren$ated
plasma
cells
• Age
standardized
incidence
rate
of
0.7-­‐2.2
per
100,000
worldwide
and
death
rate
of
0.6-­‐1.3
per
100,000
• Second
most
common
hematological
malignancy;
2%
of
all
cancers
• Median
Age
at
diagnosis
67
years,
male
predominance
• Twice
as
common
among
African
Americans,
less
common
in
Asians

65.
Infec$ous
disease
prophylaxis
• No
randomized
data
on
outcome
• Infec$ons
common
in
the
ini$al
phase
of
disease
• Bactrim/
quinolone
prophylaxis
can
be
considered
on
an
individual
basis
• Zoster
prophylaxis
in
pa$ents
on
bortezomib
• PJP
prophylaxis
for
those
on
steroids
• Role
of
IVIG
not
clear,
may
reduce
infec$ons
in
those
severely
hypogammoglobulinemic